NewsEuropeGerman Medical Cannabis Patients To Top One Million

German Medical Cannabis Patients To Top One Million

-

A REPORT into the German medical cannabis market estimates the number of patients totalled over 60,000 in less than two years since first approved.

The ‘Germany Cannabis Report’ from Prohibition Partners also states that within a few years that number will have risen to one million patients.

And, it estimates the total German cannabis market will be worth €16.2bn billion by 2028, with the medicinal cannabis market estimated to be worth €7.7bn by the same time.

This comes as Canadian firm Aphria, one of the few from that country to be currently showing a profit, say that by next year Germany will be contributing almost half it revenues. 

In a first quarter results announcement Aphria said with 2020 revenue projections estimated at $700m, its ‘German distribution business will represent slightly more than half of the total net revenue’. 

Daragh Anglim, Managing Director Prohibition Partners, says in the introduction to the report that the rapid growth of the German market ‘is unprecedented in Europe’. 

Adding: “Major change has followed across the continent but Germany remains one of the most open, promising and exciting markets in the region.” 

The report, which was released in October, last year, highlights the supply problems facing the German market which is currently reliant on imports from Canada, Holland, Portugal and Australia.

In an effort to combat this production licences were granted earlier this year, and of the 13 lots, Aphria and Aurora secured five, and Demecan received the remaining three lots. 

Each lot allows the holder to grow 200 kilograms per year for a four-year period. And the report adds: “The reality is that the German tendered facilities are not going to meet the domestic medical cannabis quantity demand.” 

It says patients requesting medical cannabis are being supported by a robust public health insurance regime, which covers 90% of the population.

The monthly allowance 100 grammes is generous and the ‘insurance companies cover all cannabis treatments and do not specify which conditions are covered’. 

Medical cannabis in Germany is very expensive, however, with an average price to patients of between €20 and €25 per gram for flower. 

In the Netherlands, medical cannabis is sold to patients for approximately €7 per gram, says the report.

Peter
Peter
Peter McCusker is an experienced news and business editor, who believes it’s time to fully embrace the multiple, proven, medical benefits of the cannabis plant.

Latest news

British People Open To Using Medical Cannabis – Yet Majority Unaware They Can Access It On Prescription 

A NEW national survey of 4,000 people has highlighted the need to improve awareness of cannabis as a medicine.  Key...

As US Hemp Cultivation Levels Plummet The Established European Industry Continues To Flourish 

DESPITE a huge decline in US hemp industry’s footprint the European industry will continue to grow, say the continent’s...

Chrystal Capital Acts As Exclusive Advisor To Change Agronomy On £9.6m Fundraise

CHRYSTAL Capital Partners LLP, is an entrepreneurial corporate finance and investment house with an established global network of Single...

European Cannabis Stocks Review: ‘End’ Of US Cannabis Bear Market Rallies European Stocks 

FOLLOWING last week’s rally there has seen something of a lull with little movement for European cannabis stocks. Last week’s...

Business of Cannabis Conference Returns to New York City on November 3rd

In this second summit, the most influential business leaders, investors and politicians gather to discuss social equity, policy and...

Curaleaf Takes Majority Stake And Forms Strategic Partnership With Germany’s Four 20 Pharma In €20m Deal

CURALEAF Holdings, Inc. (CSE: CURA) (OTCQX: CURLF), a leading U.S. provider of consumer products in cannabis, announced that Curaleaf International...

Must read

As US Hemp Cultivation Levels Plummet The Established European Industry Continues To Flourish 

DESPITE a huge decline in US hemp industry’s footprint...

European Cannabis Stocks Review: ‘End’ Of US Cannabis Bear Market Rallies European Stocks 

FOLLOWING last week’s rally there has seen something of...

You might also likeRELATED
Recommended to you